News
02-24-2010, 10:00 PM
Enzon Pharmaceuticals, Inc. today announced that the first patient has been treated in the Phase 1 study of PEG-SN38 for pediatric cancer patients. PEG-SN38 or EZN-2208 is Enzon’s PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection). The study is designed to find the recommended dose of PEG-SN38 in pediatric patients. The PEG-SN38 compound is currently being evaluated in Phase 2 studies for metastatic colorectal and breast cancer.
More... (http://www.news-medical.net/news/20100224/Enzon-Pharmaceuticals-initiates-treatment-in-PEG-SN38-Phase-1-study-for-pediatric-cancer-patients.aspx)
More... (http://www.news-medical.net/news/20100224/Enzon-Pharmaceuticals-initiates-treatment-in-PEG-SN38-Phase-1-study-for-pediatric-cancer-patients.aspx)